Restricted accessResearch articleFirst published online 2010-4
Discovery of Rifampicin as a New Anti-Glycating Compound by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry-Based Insulin Glycation Assay
An in vitro insulin glycation assay was developed for screening glycation inhibitors. The assay involves the use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the formation of glycated insulin. The assay is simple, rapid and amenable for high throughput screening. Using this assay we have discovered a strong anti-glycation activity for the anti-tuberculosis drug rifampicin. These results were compared with bovine serum albumin glucose fluorescence assay. In addition, the IC50 of rifampicin was lower than that of aminoguanidine, a known anti-glycating agent, suggesting that rifampicin is a more potent glycation inhibitor.
BrownleeM., “Advanced protein glycosylation in diabetes and aging”, Annu. Rev. Med.46, 223 (1995). doi: 10.1146/annurev.med.46.1.223
2.
AhmedN., “Advanced glycation end products—role in physiology of diabetic complication”, Diabetes Res. Clin. Practice67, 3 (2005). doi: 10.1016/j.diabres.2004.09.004
3.
VasanS.FoliesP.G.FoundsH.W., “Therapeutic potential of AGE inhibitors and breakage of AGE protein cross links”, Expert Opin. Investig. Drugs10, 1977 (2001). doi: 10.1517/13543784.10.11.1977
4.
ThornalleyP.J., “Use of aminoguanidine (pimagedin) to prevent formation of advanced glycation end products”, Arch. Biochem. Biophys.419, 31 (2003). doi: 10.1016/j.abb.2003.08.013
5.
ReddyV.P.BeyazA., “Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases”, Drug Discov. Today11, 646 (2006). doi: 10.1016/j.drudis.2006.05.016
6.
HardingJ.J.GaneaE., “Protection against glycation and post-translational modifications of protein”, Biochim. Biophys. Acta1764, 1436 (2006). doi: 10.1016/j.bbapap.2006.08.001
7.
YanagisawaK.MakitaZ.ShiroshitaK.UedaT.FusegawaT.KuwajimaS.TakeuchiM.KoikeT., “Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients”, Metabolism47, 1348 (1998) doi: 10.1016/S0026-0495(98)90303-1
8.
RahbarS.NadlerJ.L., “A new rapid method to detect inhibition of Amadori product generated by δ-gluconolactone”, Clin. Chim. Acta287, 123 (1999). doi: 10.1016/S0009-8981(99)00125-4
9.
Al-AbedY.KapurniotuA.BucalaR., “Advanced glycation end products: Detection and reversal”, Methods Enzymol.309, 152 (1999). doi: 10.1016/S0076-6879(99)09013-8
10.
LapollaA.FedeleD.TraldiP., “The role of mass spectrometry in the study of non- enzymatic protein glycation in diabetes”, Mass Spectrom. Rev.19, 279 (2000). doi: 10.1002/1098-2787(2000)19:5<279::AID-MAS3>3.0.CO;2-G
11.
KangM.J.TholeyA.HeinzleE., “Application of automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the measurement of enzyme activities”, Rapid Commun. Mass Spectrom.15, 1327 (2001). doi: 10.1002/rcm.376
12.
MaillardL.GuérineauV.Badet-DenisotM.A.BadetB.LaprévoteO.DurandP., “Monitoring enzyme–catalyzed production of glucosamine-6P by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: A new enzymatic assay for glucosamine-6P synthase”, Rapid Commun. Mass Spectrom.20, 666 (2006). Doi: 10.1002/rcm.2361
13.
KhanM.S.KulkarniM.J.KhanM.I., “Study of papain–cystatin interactions by intensity fading MALDI-ToF-MS”, Protein J.27, 7 (2008). doi: 10.1007/s10930-007-9102-3
14.
BhonsleH.S.SinghS.K.SrivastavaG.BoppanaR.KulkarniM.J., “Albumin competitively inhibits glycation of less abundant proteins”, Protein Peptide Lett.15, 663 (2008). doi: 10.2174/092986608785133690
KostolanskáJ.JakušV.BarákL., “Monitoring of early and advanced glycation in relation to the occurrence of microvascular complications in children and adolescents with type 1 diabetes mellitus”, Physiol. Res.58, 553 (2009). http://www.biomed.cas.cz/physiolres/pdf/58/58_553.pdf
17.
GreisK.D., “Mass spectrometry for enzyme assays and inhibitor screening: An emerging application in pharmaceutical research”, Mass Spectrom. Rev.26, 324 (2007). doi: 10.1002/mas.20127
18.
ShenZ.GoE.P.GamezA.AponJ.V.FokinV.GreigM.VenturaM.CrowellJ.E.BlixtO.PaulsonJ.C.StevensR.C.FinnM.G.SiuzdakG., “A mass spectrometry plate reader: Monitoring enzyme activity and inhibition with a desorption/ionization on silicon (DIOS) platform”, ChemBioChem.5, 921 (2004). doi: 10.1002/cbic.200400008
19.
HuL.JiangG.XuS.PanC.ZouH., “Monitoring enzyme reaction and screening enzyme inhibitor based on MALDI-ToF-MS platform with a matrix of oxidized carbon nanotubes”, J. Am. Soc. Mass Spectrom.17, 1616 (2006). doi: 10.1016/j.jasms.2006.07.005
20.
KimY.S.KimJ.KimC.SohnE.J.JeongY.L.H.KimH.JangD.S.KimJ.S., “KIOM-79, an inhibitor of AGEs, protein cross-linking, prevents progression of nephropathy in zucker diabetic fatty rats”, ECAM1 (2009), doi: 10.1093/ecam/nep078
21.
ShakkottaiV.G.SudhaR.BalaramP., “Gramicidin S: A peptide model for protein glycation and reversal of glycation using nucleophilic amines”, J. Peptide Res.60, 112 (2002). doi: 10.1034/j.1399-3011.2002.02901
22.
ChikaraishiY.MatsunagaN.ShimazawaM.HaraH., “Rifampicin inhibits the retinal neovascularization in vitro and in vivo”, Exp. Eye Res.86, 131 (2008). doi: 10.1016/j.exer.2007.10.003
23.
TeoS.K.StirlingD.I.ZeldisJ.B., “Thalidomide as a novel therapeutic agent: New uses for an old product”, Drug Discov. Today10, 107 (2005). doi: 10.1016/S1359-6446(04)03307-0
